NovoMedix Receives Research Grant from the National Institutes of Health (NIH) to Advance NMX1 in TBNC

SAN DIEGO, May 26, 2022 /PRNewswire/ — NovoMedix, LLC (“NovoMedix”), a biotechnology company creating novel, safe, and effective drugs to treat unmet medical needs, today announced that the National Heart, Lung, and Blood Institute division of the NIH has awarded NovoMedix a $2M Phase II…

Click here to view original post